Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30483555 | 1.00 | CYP1A2 (0.58) | CYP1A2NR1I3RAB9APDE10ANPC1 | |
| SCHEMBL18806847 | 0.87 | RAB9A (0.49) | CYP1A2NR1I3RAB9ANPC1BCHE | |
| SCHEMBL8775191 | 0.86 | BCHE (0.48) | CYP1A2NR1I3RAB9APDE10ABCHE | |
| SCHEMBL28572207 | 0.86 | CYP1A2 (0.57) | CYP1A2RAB9APDE10ANPC1KMT2A | |
| SCHEMBL8776966 | 0.82 | PDE10A (0.46) | CYP1A2NR1I3RAB9APDE10ABCHE | |
| SCHEMBL12386966 | 0.81 | CYP1A2 (0.68) | CYP1A2RAB9APDE10ANPC1KMT2A | |
| SCHEMBL29928771 | 0.81 | CYP1A2 (0.68) | CYP1A2RAB9APDE10ANPC1KMT2A | |
| SCHEMBL28856766 | 0.80 | CYP1A2 (0.58) | CYP1A2RAB9ANPC1BCHEACHE | |
| SCHEMBL16218727 | 0.80 | BIRC5 (0.59) | CYP1A2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30674461 | 0.80 | CYP1A2 (0.58) | CYP1A2RAB9APDE10ANPC1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229222-A | Method for synthesizing quinazoline by dehydrogenation of tetrahydroquinazoline | 西安石油大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-112941549-A | Synthetic method of quinazoline derivative, benzoxazine derivative and benzothiazole derivative | 石河子大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-109879820-A | A kind of synthetic method of quinazolinone heterocyclic compound | 扬州大学 | 2019-06-14 | — | — | CN | disclosed |
| US-20180083203-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2018-03-22 | — | — | US | disclosed |
| CN-104496915-B | Synthetic method of quinazolinone aromatic compound | 华侨大学 | 2017-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180083203-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | NES, CACNA2D4, PGLS | CYP1A2 3552/4885NR1I3 3648/4885RAB9A 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.